Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
Open Access
- 4 May 2020
- journal article
- research article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 16 (17), 1199-1210
- https://doi.org/10.2217/fon-2020-0212
Abstract
Aim: Immunomodulatory mechanisms contributing to angiogenic inhibition in renal tumors are not well characterized. We report associations between efficacy and tumor-associated immune cells and mRNA/miRNA expression in patients from AXIS. Materials & methods: Immunohistochemistry (n = 52) and mRNA/miRNA expression analyses (n = 72) were performed on tumor samples. Results: In axitinib-treated patients, higher CXCR4 and TLR3 expression, respectively, was associated with longer progression-free survival (hazard ratio [95% CI]: 0.3 [0.1–0.8] and 0.4 [0.2–0.9]) and showed interaction with treatment (p = 0.029 and p < 0.001); lower CCR7 expression was associated with objective response (odds ratio: 0.1 [95% CI: 0.01–1.0]) and longer overall survival (hazard ratio: 3.9 [95% CI: 1.4–10.3]). Conclusion:CCR7, CXCR4 and TLR3 expression levels may be prognostic/predictive of clinical benefit with axitinib. Clinical trial identifier: ClinicalTrials.gov NCT00678392.Keywords
This publication has 37 references indexed in Scilit:
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 2018
- Renal cell carcinomaNature Reviews Disease Primers, 2017
- MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patientsOncotarget, 2016
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications, 2016
- Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancerOncotarget, 2015
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic SettingClinical Cancer Research, 2015
- Meta-analysis of Clear Cell Renal Cell Carcinoma Gene Expression Defines a Variant Subgroup and Identifies Gender Influences on Tumor BiologyEuropean Urology, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival PatternsGenes & Cancer, 2010
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3Clinical Cancer Research, 2008